Baidu
map

Eur Cell Mater:通过非病毒基因递送BMP-2/6和BMP-2/7形成异二聚体促进骨生成

2018-04-03 MedSci MedSci原创

非病毒基因传递是一种安全的技术以持续生理剂量的方式来释放骨形态发生蛋白(BMP)。多种BMP的共同递送可形成更有效的BMP异二聚体。在该研究中,研究人员评估了BMP-2/6和BMP-2/7的非病毒共转运,以产生异二聚体。使用编码BMP异构体(pBMP)的质粒DNA对山羊MSCs进行非病毒转染,已知与成骨有关的BMP异构体:BMP-2,-6或-7。结果,BMP-2,-6和-7可在MSCs中产生并且可

非病毒基因传递是一种安全的技术以持续生理剂量的方式来释放骨形态发生蛋白(BMP)。多种BMP的共同递送可形成更有效的BMP异二聚体。在该研究中,研究人员评估了BMP-2/6和BMP-2/7的非病毒共转运,以产生异二聚体。

使用编码BMP异构体(pBMP)的质粒DNA对山羊MSCs进行非病毒转染,已知与成骨有关的BMP异构体:BMP-2,-6或-7。结果,BMP-2,-6和-7可在MSCs中产生并且可检测长达14天,且其联合递送(pBMP-2与pBMP-6或pBMP-7)用于产生BMP-2/6和BM -2/7异二聚体。通过夹心酶联免疫吸附测定(ELISA)验证异二聚体蛋白的形成和分泌。

结果显示,产生的BMP和异源二聚体具有生物活性,细胞和MSCs的证实了这点。为了评估骨形成,将转染的MSCs接种到陶瓷支架上并将其皮下植入裸鼠中。在pBMP-2/6条件下骨形成明显增强,并且在pBMP-2/7和pBMP-6同二聚体条件下观察到更多骨形成的趋势。在pBMP-2,pBMP-7或对照条件中未发现骨。

总之,与BMP同型二聚体相比,用pBMP-6或-7同时递送pBMP-2可产生有利于骨形成的异二聚体。BMP序列的组合可以减少对高BMP蛋白剂量的需要并且可以延长生长因子的可用时间。

原始出处:

Loozen LD, Vandersteen A, et al., Bone formation by heterodimers through non-viral gene delivery of BMP-2/6 and BMP-2/7. Eur Cell Mater. 2018 Mar 28;35:195-208. doi: 10.22203/eCM.v035a14.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
    2018-09-24 HNYYM
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
    2018-08-15 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1634029, encodeId=d01c1634029de, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Sep 24 16:07:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960802, encodeId=a8af196080249, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Aug 15 14:07:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950362, encodeId=d7af195036299, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Tue Jan 29 17:07:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870534, encodeId=bbb618e0534cd, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Aug 01 07:07:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819560, encodeId=47e6181956082, content=<a href='/topic/show?id=7df79956800' target=_blank style='color:#2F92EE;'>#非病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99568, encryptionId=7df79956800, topicName=非病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Sun May 27 13:07:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642650, encodeId=fcf5164265047, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Fri Oct 12 02:07:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]

相关资讯

Spine:脊柱融合术中使用BMP骨不连无改善

2002年,美国 FDA 批准骨形态发生蛋白(bone morphogenetic protein, BMP)用于单节段前路脊柱融合术。 自从BMP上市以来,一些研究陆续报道了BMP的并发症,但BMP一直还在使用的原因之一是有研究证实BMP能预防髂骨植骨融合(ICBG)的疼痛和并发症,还能降低脊柱融合术的失败率,但其中很多研究采用影像学评估骨不连的方法。 Guppy等认为这中方法并

Clin oral invest:重组人骨形态发生蛋白-2和-9对大鼠颅骨临界缺损后骨形成影响的比较

在骨形态发生蛋白(BMP)家族成员中,BMP-2和BMP-9已经显示出有力的骨诱导潜能。然而,体内骨再生潜力的差异仍不清楚。本研究旨在比较重组人(rh)BMP-2和rhBMP-9对大鼠颅骨临界缺损(CSD)骨形成的影响。

Stem cells:内源性BMP的信号强弱,影响诱导多能干细胞分化成角膜上皮细胞的能力。

角膜是我们眼睛的最外层,可将光折射到视网膜上。透明的角膜上皮由角膜缘干细胞(LSCs)再生,LSCs功能异常会导致LSCs缺陷病(LSCD)。从患者健康的眼睛中获得自体LSCs,通过体外扩增,然后移植到LSCs受损/缺陷的眼睛。研究人员研究人类诱导多能干细胞(hiPSC)分化成角膜缘上皮样细胞的潜能,作为双侧完全性LSCD患者进行自体干细胞治疗的来源。在分化的前九天,予以骨形成蛋白4(BMP4)、

Blood:CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。

BCR-ABL特异性的酪氨酸酶抑制剂(TKI)可影响慢性粒细胞白血病(CML)患者的预后,使危及生命的疾病转为慢性病。但是,TKI并不是十分有效,因为多数患者的骨髓内仍有白血病干细胞(LSC)及其祖细胞残留,治疗终止后可复发。

J Clin Periodontol:小型猪用双生长因子改善下颌骨嵴鞍型缺损修复的实验研究

为了验证在聚合物载体中,在rhBMP2中添加少量rhVEGF,低剂量的rhBMP2可以实现与单独使用rhBMP2相当的修复效果。

Neurosurgery:骨形态发生蛋白(BMP)可能增加良性肿瘤风险

发表在九月Neurosurgery杂志上的一项研究报告称:用骨形态发生蛋白(BMP)进行脊柱融合术的患者似乎患良性肿瘤的风险增加,但患癌症的风险不增加。【原文下载】 美国杜克大学医学中心Nandan博士和他的同事分析了脊柱融合手术中接受BMP的近4,700名患者的癌症和良性肿瘤风险。骨形态发生蛋白是一种生长因子,可以促进新骨形成。 它是FDA批准的用于一种特定类

Baidu
map
Baidu
map
Baidu
map